• Something wrong with this record ?

Cancer detection rates and inter-examiner variability of MRI/TRUS fusion targeted biopsy and systematic transrectal biopsy

M. Zalesky, J. Stejskal, I. Minarik, V. Adamcova, M. Babjuk, R. Zachoval

. 2020 ; 164 (3) : 314-319. [pub] 20191010

Language English Country Czech Republic

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc21021184

Grant support
NV15-27047A MZ0 CEP Register

BACKGROUND: Software-based MRI/TRUS fusion biopsy depends on the coordination of several steps, and inter-examiner differences could influence the results. The aim of this bicentric prospective study was to compare the detection rates of MRI/TRUS fusion targeted biopsy (TG) and systematic biopsy (SB), and the detection rates of examiners with different levels of previous experience in prostate biopsy. METHODS: A total of 419 patients underwent MRI based on a suspicion of prostate cancer with elevated PSA levels. MRI was positive in 395 patients (221 in the first biopsy group [FB] and 174 in the repeated biopsy group [RB]). A subsequent TG, followed by a SB, was performed on these patients by four different examiners. RESULTS: In the detection of clinically significant prostate cancer, a significant difference was found for TG+SB against SB in the RB group (35.1% vs. 25.3%, P=0.047). In the detection of clinically insignificant prostate cancer, the SB had a significantly higher detection rate than TG in both subgroups (FB: 11.9% vs. 4.7%, P=0.008; RB: 13.8% vs. 6.9%, P=0.034). A significant difference was found between the four examiners in the FB for TG (P=0.028), SB (P=0.036), and TG+SB (P=0.017). CONCLUSION: MRI/TRUS TG in combination with SB had significantly higher detection rates than SB in the RB group only. Differences in detection rates between examiners were dependent on the level of previous experience with TRUS guided biopsy.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21021184
003      
CZ-PrNML
005      
20210908164858.0
007      
ta
008      
210806s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2019.050 $2 doi
035    __
$a (PubMed)31602045
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Záleský, Miroslav $7 ola2004220082 $u Department of Urology, Thomayer Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Cancer detection rates and inter-examiner variability of MRI/TRUS fusion targeted biopsy and systematic transrectal biopsy / $c M. Zalesky, J. Stejskal, I. Minarik, V. Adamcova, M. Babjuk, R. Zachoval
504    __
$a Literatura
520    9_
$a BACKGROUND: Software-based MRI/TRUS fusion biopsy depends on the coordination of several steps, and inter-examiner differences could influence the results. The aim of this bicentric prospective study was to compare the detection rates of MRI/TRUS fusion targeted biopsy (TG) and systematic biopsy (SB), and the detection rates of examiners with different levels of previous experience in prostate biopsy. METHODS: A total of 419 patients underwent MRI based on a suspicion of prostate cancer with elevated PSA levels. MRI was positive in 395 patients (221 in the first biopsy group [FB] and 174 in the repeated biopsy group [RB]). A subsequent TG, followed by a SB, was performed on these patients by four different examiners. RESULTS: In the detection of clinically significant prostate cancer, a significant difference was found for TG+SB against SB in the RB group (35.1% vs. 25.3%, P=0.047). In the detection of clinically insignificant prostate cancer, the SB had a significantly higher detection rate than TG in both subgroups (FB: 11.9% vs. 4.7%, P=0.008; RB: 13.8% vs. 6.9%, P=0.034). A significant difference was found between the four examiners in the FB for TG (P=0.028), SB (P=0.036), and TG+SB (P=0.017). CONCLUSION: MRI/TRUS TG in combination with SB had significantly higher detection rates than SB in the RB group only. Differences in detection rates between examiners were dependent on the level of previous experience with TRUS guided biopsy.
650    _2
$a senioři $7 D000368
650    _2
$a palpační vyšetření konečníku $x metody $x normy $7 D051517
650    _2
$a lidé $7 D006801
650    _2
$a ultrazvukem navigovaná biopsie $x metody $x normy $7 D061705
650    _2
$a magnetická rezonanční tomografie $x metody $x normy $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a prospektivní studie $7 D011446
650    _2
$a nádory prostaty $x diagnóza $x patofyziologie $7 D011471
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a intervenční ultrasonografie $x metody $x normy $7 D018084
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stejskal, Jiří $7 xx0236659 $u Department of Urology, Thomayer Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Minárik, Ivo, $d 1977- $7 xx0227806 $u Department of Urology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
700    1_
$a Adamcová, Vanda $7 xx0236641 $u Department of Urology, Thomayer Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Babjuk, Marko, $d 1961- $7 jn20020716353 $u Department of Urology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
700    1_
$a Zachoval, Roman, $d 1967- $7 mzk2004248672 $u Department of Urology, Thomayer Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 164, č. 3 (2020), s. 314-319
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31602045 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20210806 $b ABA008
991    __
$a 20210906172645 $b ABA008
999    __
$a ok $b bmc $g 1694791 $s 1141637
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 164 $c 3 $d 314-319 $e 20191010 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
GRA    __
$a NV15-27047A $p MZ0
LZP    __
$b NLK118 $a Pubmed-20210806

Find record

Citation metrics

Archiving options